KRAS and colorectal carcinoma: This first-in-human trial is testing the safety and efficacy of JDQ443 alone or in combination with TNO155 (SHP2 inhibitor) and/or tislelizumab (anti-PD1 antibody) in patients with KRAS-G12C-mutated solid tumors, including NSCLC and CRC patients.386 At its recommended phase 2 dose (RP2D), JDQ443 showed an ORR of 41.7% in NSCLC patients.387 Now, a phase III trial is underway to assess the effectiveness and safety of JDQ443 as a standalone treatment versus docetaxel in patients with KRAS-G12C mutant NSCLC (NCT05132075; KontRASt-02).